Overview
Astellas Pharma Inc. is a Tokyo-headquartered pharmaceutical company that researches, develops, manufactures, and supplies medicines. Its stated purpose is to improve health worldwide through innovative, reliable pharmaceutical products, and its vision is to be at the forefront of healthcare change by turning innovative science into value for patients.[1]
Its portfolio spans oncology, ophthalmology, urology, immunology, and women’s health, with products including PADCEV, XTANDI, XOSPATA, and VEOZA.[2][3] Astellas operates in more than 70 countries and areas.[4] For fiscal 2025, it reported revenue of ¥2,139.2 billion and 14,099 employees.[5][6] [3][1][2][4][5][6]
Products & services
Astellas’ marketed products include XTANDI (enzalutamide), a prostate-cancer medicine; PADCEV (enfortumab vedotin), an antibody-drug conjugate targeting Nectin-4 for urothelial cancer; VYLOY (zolbetuximab), an anti-CLDN18.2 antibody used with chemotherapy for eligible gastric or gastroesophageal-junction cancers; XOSPATA (gilteritinib) for FLT3-mutated acute myeloid leukemia; VEOZAH/VEOZA (fezolinetant), an NK3 receptor antagonist for menopausal vasomotor symptoms; and IZERVAY (avacincaptad pegol), an intravitreal complement C5 inhibitor for geographic atrophy secondary to age-related macular degeneration. Indications and brand names can vary by market.[2][7] Product label sources provide prescribing details for VYLOY, IZERVAY, and VEOZAH.[8][9][10]
XTANDI generated ¥960.8 billion in FY2025 sales, approximately 44.9% of Astellas’ ¥2,139.2 billion total revenue for that year.[11] [7][2][8][9][10][11]
Geographic presence
Astellas is headquartered in Tokyo and operates in more than 70 countries and areas. In FY2025, revenue was ¥2,139.2 billion. Reported regional revenue included the United States, ¥940.2 billion (44.0% of total); Established Markets, ¥563.6 billion (26.3%); Japan, ¥289.0 billion (13.5%); and China, ¥101.5 billion (4.7%). Percentages are calculated from reported revenue and rounded to one decimal.[11] Astellas describes Established Markets as Europe and Canada, and its China region as China and Hong Kong. Its International Markets span Latin America, the Middle East, Africa, Southeast and South Asia, Russia, Korea, Taiwan and Australia, among other markets.[12][13][14]
The company identifies Japan as its global headquarters, with regional headquarters in China, the UK for Established Markets, and Singapore for International Markets.[15] At FY2025 year-end, it reported 14,099 employees globally: 4,105 in Japan, 3,106 in the United States, 3,512 in Established Markets, 1,283 in China, and 2,093 in International Markets.[6] Astellas reports 15 global R&D sites, highlighting locations in Boston and South San Francisco in the United States and Tsukuba in Japan.[16] Its listed manufacturing locations include sites in Japan, Ireland, the United States, and China.[17] [11][12][13][14][15][6][16][17][11][15][6][16][17]
Business segments
Astellas reports one pharmaceutical-business reportable segment rather than separate financial segments by therapeutic area. It therefore represents approximately 100% of consolidated revenue; FY2025 revenue was ¥2,139.2 billion for the year ended March 31, 2026.[11][18]
Separately, the company identifies four R&D “Primary Focuses”: Blindness and Regeneration, Genetic Regulation, Immuno-Oncology, and Induced Proximity. These are research and development focus areas, not reported revenue segments, and Astellas does not provide segment revenue percentages for them.[19]
Company history
Astellas traces its origins to two Japanese pharmaceutical companies: Fujisawa Shoten, founded by Tomokichi Fujisawa in 1894, and Yamanouchi Yakuhin Shokai, founded by Kenji Yamanouchi in 1923. Their successors, Fujisawa Pharmaceutical and Yamanouchi Pharmaceutical, merged on April 1, 2005, to form Astellas Pharma Inc.[20][21]
The company’s earlier milestones included the 1993 launch of the immunosuppressant Prograf. It expanded through acquisitions including Agensys in 2007 and OSI Pharmaceuticals in 2010, and launched the cancer medicine XTANDI in the United States in 2012. Further acquisitions from 2016 onward broadened its research and product portfolio; among later milestones were U.S. approvals of XOSPATA in 2018 and PADCEV in 2019. In 2023, Astellas completed its acquisition of Iveric Bio, whose IZERVAY treatment received U.S. approval that year; VYLOY was approved in Europe and the United States in 2024.[20][22][23][24][25][26][27][28][29][30] [20][21][22][23][24][25][26][27][28][29][30]
Sources
- www.astellas.com[1]
- www.astellas.com[2]
- ASTELLAS PHARMA INC — Presentation (2025 Q 1)
- www.astellas.com[4]
- www.astellas.com[5]
- www.astellas.com[6]
- www.astellas.com[8]
- www.astellas.com[9]
- www.astellas.com[10]
- www.astellas.com[11]
- www.astellas.com[15]
- www.astellas.com[16]
- www.astellas.com[17]
- www.astellas.com[18]
- www.astellas.com[19]
- www.astellas.com[20]
- newsroom.astellas.com[21]
- newsroom.astellas.com[22]
- newsroom.astellas.com[23]
- newsroom.astellas.com[24]
- newsroom.astellas.com[25]
- newsroom.astellas.com[26]
- newsroom.astellas.com[27]
- newsroom.astellas.com[28]
- newsroom.astellas.com[29]
- newsroom.astellas.com[30]
Continue your research
From company context to financial detail.
Explore original sources and worldwide fundamental financial data and intelligence with Finbar.
Explore ASTELLAS PHARMA INC in Finbar ↗